Rayon Swab ,Micro Head Foam Swab ,Lint Free Polyester Swab,Oral Swab Sticks Hunan Kangfutai Medical Devices Co., Ltd. , https://www.3kfut.com
Business Club March 25th In 2010, the global pharmaceutical market sales reached US$850 billion, of which biotech drugs and generic drugs hit new highs, reaching US$140 billion and US$120 billion respectively. Outside the United States, sales of biosimilars have also exceeded $1 billion.
Of the 20 best-selling drugs in the world in 2010, Pfizer’s atorvastatin calcium for cholesterol lowering ranks first, reaching US$ 11.8 billion. Although its patent protection period expires in March 2010, the company reached an agreement with Ranbaxy Pharmaceuticals Inc., an Indian generic drug maker, and will eventually expire in November 2011. In the second place, clopidogrel bisulfate used to inhibit thrombosis in patients with coronary artery disease, peripheral vascular disease, and cerebrovascular disease was developed in cooperation with Bristol-Myers Squibb Pharmaceuticals and France's Sanofi-Aventis pharmaceutical company. (The patent protection period expires in November 2011.) In the last two years, the annual sales of clopidogrel hydrogen sulfate have exceeded US$9 billion, making it the second most popular global drug. Jointly developed by Johnson & Johnson Pharmaceuticals, Merck & Co., Ltd. and Tanabe Mitsubishi Pharmaceutical Co., Ltd. for the treatment of rheumatoid arthritis (RA), ulcerative colitis (UC), Crohn's disease (CD), psoriasis Infliximab (Ps), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) ranks third, and infliximab may be in atorvastatin calcium and clopidogrel sulfate. After the expiration of its patent protection period, it ranked first in the world's best-selling drugs.
Of the 12 best-selling drugs with sales of US$5 billion and above in 2010, 6 were biologics; of the 20 drugs with sales exceeding US$4 billion, 8 were biologics. 2009 Several "blockbuster" class of drugs due to patent protection period expired drugs being squeezed world's best selling list, leading to 2010, the global pharmaceutical market sales rankings have been greatly changed, but the Swiss pharmaceutical company Roche is still The pharmaceutical company with the highest sales of biologics, anticancer drugs and monoclonal antibodies. Rituximab, developed by Roche for the treatment of leukemia and rheumatoid arthritis, has a patent protection period in Europe that expires in 2014 and will expire in the United States in 2015. Generic pharmaceutical companies hope generic biotech drugs and participate in market competition in the near future, but at present these impending loss of patent protection for biotech drugs is also a lack of clear regulations, original biotech drug drugmaker strict supervision and research costs Too high makes the prospects for these drugs confusing.
2010 best-selling categories of drugs are central nervous system drugs, cardiovascular drugs and anti-tumor drugs; in terms of biological agents, the best-selling categories of drugs are monoclonal antibodies, vaccines, and tumor necrosis factor inhibitors.